ORAGENICS INC
OGENNYSE
$0.55
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↓ -61.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.4M
Enterprise Value
-$3.7M
P/E
—
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$984.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-15921.6%
ROIC
-10147.1%
Debt / Equity
—
Net Cash
$6.1M
Return 1Y
-61.6%
Company profile
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. NT-CoV2-1, an intranasal vaccine candidate provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.
- CEO
- Kimberly M. Murphy
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Florida
- Website
- oragenics.com
Earnings
OGEN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.51↓ -86.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $86,987.00 | $131,521.00 | $37,653.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$26.6M | -$15.8M | -$14.4M | -$20.9M | -$10.6M | -$9.4M |
| Net income | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$1.1B | -$984.2M |
| Diluted EPS | — | — | -$7.11 | -$9.18 | -$47.88 | -$4.56 |
| Operating cash flow | -$17.0M | -$13.5M | -$15.2M | -$7.3M | -$8.6M | -$9.2M |
| Free cash flow | — | -$13.5M | -$15.4M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -18130.3% | -10964.6% | -55519.9% | — | — |
| Net margin | — | -18062.0% | -10864.0% | -54858.1% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.3M | -$2.4M | -$3.4M | -$2.0M | -$1.7M | -$3.1M | -$2.5M | -$2.3M |
| Net income | -$2.3M | -$2.5M | -$1.0B | -$2.2M | -$2.3M | -$3.1M | -$976.7M | -$2.2M |
| Diluted EPS | -$15.27 | -$11.32 | -$20.59 | -$3.65 | -$3.10 | -$1.96 | $4.15 | -$0.51 |
| Operating cash flow | -$1.5M | -$2.0M | -$2.0M | -$2.1M | -$1.3M | -$3.0M | -$2.8M | -$2.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-12 | Telling Fred | Sale | 210 | $0.94 | $198.37 | filing |
| 2025-12-12 | Telling Fred | Sale | 210 | $0.94 | $198.37 | filing |
| 2025-06-18 | Odyssey Health, Inc. | Sale | 5,044 | $4.26 | $21,487.44 | filing |
| 2025-06-17 | Odyssey Health, Inc. | Sale | 2,000 | $4.46 | $8,920.00 | filing |
| 2025-06-16 | Odyssey Health, Inc. | Sale | 5,000 | $4.45 | $22,250.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.